# Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

> **NCT06919003** · PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 180 (estimated)

## Conditions studied

- Kidney Transplant

## Interventions

- **BIOLOGICAL:** Berinert
- **OTHER:** Placebo for Berinert

## Key facts

- **NCT ID:** NCT06919003
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2031-05-30
- **Final completion:** 2032-05-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06919003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06919003, "Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06919003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*